Literature DB >> 8501241

Anticandidal activity and interleukin-1 beta and interleukin-6 production by polymorphonuclear leukocytes are preserved in subjects with AIDS.

A Cassone1, C Palma, J Y Djeu, F Aiuti, I Quinti.   

Abstract

Polymorphonuclear granulocytes (PMN; or neutrophils) from uninfected or human immunodeficiency virus-infected subjects were tested for their ability to inhibit growth of Candida albicans and produce interleukin-1 beta (IL-1 beta) and IL-6 in vitro. It was seen that PMN from AIDS (Centers for Disease Control stage IV) patients expressed equal if not greater anticandidal activity compared with the activity expressed by neutrophils from all other subjects examined. On exposure to granulocyte macrophage-colony-stimulating factor or to a mannoprotein constituent (MP-F2) from C. albicans itself, PMN from AIDS patients showed enhanced antifungal activity and production of remarkable quantities of IL-1 beta and IL-6. These findings suggest that the functional abilities of PMN to inhibit Candida growth and secrete relevant proinflammatory and immunomodulatory cytokines are intrinsically preserved in AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501241      PMCID: PMC262937          DOI: 10.1128/jcm.31.5.1354-1357.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation.

Authors:  M Ellis; S Gupta; S Galant; S Hakim; C VandeVen; C Toy; M S Cairo
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

2.  Comparison of candidacidal and candidastatic activities of human neutrophils.

Authors:  P G Sohnle; C Collins-Lech
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

Review 3.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

4.  Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome.

Authors:  R S Klein; C A Harris; C B Small; B Moll; M Lesser; G H Friedland
Journal:  N Engl J Med       Date:  1984-08-09       Impact factor: 91.245

5.  Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome.

Authors:  A Lazzarin; C Uberti Foppa; M Galli; A Mantovani; G Poli; F Franzetti; R Nóvati
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

6.  A rapid [3H]glucose incorporation assay for determination of lymphoid cell-mediated inhibition of Candida albicans growth.

Authors:  J Y Djeu; A Parapanissios; D Halkias; H Friedman
Journal:  J Immunol Methods       Date:  1986-08-21       Impact factor: 2.303

7.  Identification of a mannoprotein fraction from Candida albicans that enhances human polymorphonuclear leukocyte (PMNL) functions and stimulates lactoferrin in PMNL inhibition of candidal growth.

Authors:  C Palma; D Serbousek; A Torosantucci; A Cassone; J Y Djeu
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

8.  Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients.

Authors:  G C Baldwin; J C Gasson; S G Quan; J Fleischmann; R Weisbart; D Oette; R T Mitsuyasu; D W Golde
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

Review 9.  Candida and AIDS: evidence for protective antibody.

Authors:  R Matthews; J Burnie; D Smith; I Clark; J Midgley; M Conolly; B Gazzard
Journal:  Lancet       Date:  1988-07-30       Impact factor: 79.321

10.  Hierarchical pattern of mucosal candida infections in HIV-seropositive women.

Authors:  N Imam; C C Carpenter; K H Mayer; A Fisher; M Stein; S B Danforth
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

View more
  10 in total

1.  Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans.

Authors:  M J Gomez; A Torosantucci; S Arancia; B Maras; L Parisi; A Cassone
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis.

Authors:  C Bromuro; R La Valle; S Sandini; F Urbani; C M Ausiello; L Morelli; C Fé d'Ostiani; L Romani; A Cassone
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 3.  Prospects for the development of fungal vaccines.

Authors:  G S Deepe
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 4.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans.

Authors:  G Arancia; A Molinari; P Crateri; A Stringaro; C Ramoni; M L Dupuis; M J Gomez; A Torosantucci; A Cassone
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

6.  A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.

Authors:  A Mencacci; A Torosantucci; R Spaccapelo; L Romani; F Bistoni; A Cassone
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.

Authors:  Mark Duval; Marshall R Posner; Lisa A Cavacini
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

Review 8.  T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design.

Authors:  L Romani; E Cenci; A Menacci; F Bistoni; P Puccetti
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

9.  CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1.

Authors:  Miriam Marquis; Daniel Lewandowski; Véronique Dugas; Francine Aumont; Serge Sénéchal; Paul Jolicoeur; Zaher Hanna; Louis de Repentigny
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 10.  Candidiasis--do we need to fight or to tolerate the Candida fungus?

Authors:  M Raska; J Bĕláková; M Krupka; E Weigl
Journal:  Folia Microbiol (Praha)       Date:  2007       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.